ArticleExperimental and therapeutic medicine2014
Effects of metformin on endothelial function in type 2 diabetes.
Article in Experimental and therapeutic medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Metformin monotherapy for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020 · on this mapPooled it
- Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.Cardiovascular diabetology · 2018Trial
- Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.Cardiovascular diabetology · 2016Trial
- Empagliflozin and Arterial Stiffness in Patients with Type 2 Diabetes: A Real-World Case-Control StudyEndocrine, metabolic & immune disorders drug targets · 2026Article
- Pathophysiology and Clinical Management of Bile Acid Diarrhea.Journal of clinical medicine · 2022Review
- The Hormetic Effect of Metformin: "Less Is More"?International journal of molecular sciences · 2021Review
- Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis.Journal of clinical medicine · 2020Review
- [Effect of traditional Chinese medicine for replenishing qi, nourishing yin and activating blood on renal Notch/Hes1 signaling in rats with diabetic nephropathy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- The Novel Compound Sul-121 Preserves Endothelial Function and Inhibits Progression of Kidney Damage in Type 2 Diabetes Mellitus in Mice.Scientific reports · 2017Article
- Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from Glycemia Control: Comparison to Vildagliptin.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to examine the effect of metformin on endothelial function in patients with type 2 diabetes mellitus (T2DM). In total, 93 patients with T2DM and dissatisfactory glycemic control were randomly assigned to the metformin and pioglitazone groups and changes in vascular endothelial function were subsequently observed. Blood sugar levels and the insulin resistance (IR) index of the patients prior to treatment were lower than those following 12 months of treatment. In addition, fasting and postprandial insulin levels and the insulin function index were higher compared with those obtained following 12 months of treatment (P<0.05). Following 12 months of treatment, the body mass index (BMI) in the metformin group was lower than that in the pioglitazone group (P<0.05). Vascular endothelial function had improved in the groups following 12 months of treatment, when compared with the levels prior to treatment (P<0.05). Following 12 months of treatment, endothelial function in the metformin group had improved markedly compared with that in the pioglitazone group (P<0.05). Therefore, the administration of metformin and pioglitazone in patients with T2DM may improve insulin function, reduce the role of IR and improve endothelial function. Metformin is more successful than pioglitazone in reducing BMI and improving endothelial function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.